The effect of K drug combined with Ipilimumab

K drug refers to Pembrolizumab in clinical practice in China. The effect of pembrolizumab combined with ipilimumab (Ipilimumab) has shown positive results in the treatment of various tumors. Data from a phase III clinical study called KEYNOTE-006 showed that pembrolizumab combined with ipilimumab improved overall survival (OS) and progression-free survival (PFS) in some patients with advanced melanoma. Specifically, the 5-year overall survival (OS) was 43% for pembrolizumab and 33% for ipilimumab. Furthermore, all patients who achieved complete response (CR) and completed 2 years of pembrolizumab treatment were still alive after 5 years.